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Objectives: To evaluate the cost-effectiveness of alternative approaches to revasculari-
zation for patients with three-vessel or left main coronary artery disease (CAD).
Background: Previous studies have demonstrated that, despite higher initial costs,
long-term costs with bypass surgery (CABG) in multivessel CAD are similar to those
for percutaneous coronary intervention (PCI). The impact of drug-eluting stents (DES)
on these results is unknown. Methods: The SYNTAX trial randomized 1,800 patients
with left main or three-vessel CAD to either CABG (n 5 897) or PCI using paclitaxel-
eluting stents (n 5 903). Resource utilization data were collected prospectively for all
patients, and cumulative 1-year costs were assessed from the perspective of the U.S.
healthcare system. Results: Total costs for the initial hospitalization were $5,693/
patient higher with CABG, whereas follow-up costs were $2,282/patient higher with
PCI due mainly to more frequent revascularization procedures and higher outpatient
medication costs. Total 1-year costs were thus $3,590/patient higher with CABG, while
quality-adjusted life expectancy was slightly higher with PCI. Although PCI was an
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economically dominant strategy for the overall population, cost-effectiveness varied
considerably according to angiographic complexity. For patients with high angio-
graphic complexity (SYNTAX score > 32), total 1-year costs were similar for CABG and
PCI, and the incremental cost-effectiveness ratio for CABG was $43,486 per quality-
adjusted life-year gained. Conclusions: Among patients with three-vessel or left main
CAD, PCI is an economically attractive strategy over the first year for patients with low
and moderate angiographic complexity, while CABG is favored among patients with
high angiographic complexity. VC 2011 Wiley Periodicals, Inc.
Key words: cost-benefit analysis; revascularization; randomized controlled trial;
restenosis
INTRODUCTION
Previous randomized trials comparing percutaneous
coronary intervention (PCI) and coronary artery bypass
grafting (CABG) in patients with multivessel coronary
artery disease (CAD) have demonstrated similar rates
of adverse events including death and myocardial in-
farction (MI) over 5–10 years [1–6]. Given comparable
outcomes for irreversible cardiovascular events, sec-
ondary considerations including quality of life and
cost-effectiveness become increasingly relevant in
choosing between these alternative revascularization
strategies.
Previous economic studies have compared both con-
ventional balloon angioplasty and bare metal stents
with CABG. In general, these studies have demon-
strated that PCI is less costly as an initial strategy, but
that follow-up costs are substantially higher—driven
predominantly by higher rates of repeat revasculariza-
tion—resulting in roughly comparable costs within the
first several years of follow-up [7–9]. More recently,
the introduction of drug-eluting stents (DES) has led to
substantial reductions in restenosis and rates of repeat
revascularization compared with previous PCI techni-
ques [10]. Although numerous studies have examined
the cost-effectiveness of DES versus bare metal stents
[11–13], whether the benefits of DES have led to im-
portant changes in the balance of costs and benefits
between PCI and CABG is unknown. In addition, most
previous studies of coronary revascularization in multi-
vessel CAD have excluded patients with left main dis-
ease. Consequently, the economic benefits of a contem-
porary PCI strategy for these complex patient subsets
are unknown as well.
The Synergy between PCI with TAXUS and Cardiac
Surgery (SYNTAX) trial is the first randomized clini-
cal trial to compare PCI with DES versus CABG for
patients with three-vessel and left main CAD. Given
the increasing importance of economic considerations
in the current healthcare environment, a prospectively
designed health economic evaluation was embedded
within the SYNTAX trial. By collecting detailed
resource utilization data, we sought to directly evaluate
the cost-effectiveness of DES versus CABG and to
extend insights from previous clinical trials to patients
with the most complex forms of CAD. This report
describes the 1-year results of this ancillary economic
study, performed from the perspective of the U.S.
healthcare system.
METHODS
Trial Design and Treatment Protocol
The SYNTAX trial design and methods have been
described previously [14,15]. Between March 2005 and
April 2007, a total of 1,800 patients with three-vessel
or left main CAD suitable for equivalent revasculariza-
tion by either PCI or CABG were randomized to either
technique. In both groups, patients were treated with
the goal of achieving complete revascularization of all
vessels at least 1.5 mm in diameter. Patients random-
ized to CABG underwent treatment using standard
techniques. All PCI procedures utilized paclitaxel-elut-
ing stents (TAXUS Express; Boston Scientific, Natick,
MA).
The Institutional Review Board at each center
approved the protocol, and all patients provided written
informed consent. The study was designed collabora-
tively by the SYNTAX trial steering committee and
the sponsor, Boston Scientific and is registered at the
National Institute of Health website (www.clinical-
trials.gov) as identifier NCT00114972.
Assessment of Resource Utilization and Clinical
Follow-up
Case report forms documenting patient characteris-
tics, procedural details, medical resource utilization,
and clinical outcomes during the initial hospitalization
and 1-year follow-up period were completed by a
research coordinator at each site. All components of
the primary clinical endpoint (death, MI, stroke, repeat
revascularization) were reviewed by an independent
clinical events committee that was blinded to treatment
assignment. Other clinical outcomes (e.g., wound infec-
tion, arrhythmias etc.) and measures of resource
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utilization (e.g., length of stay) were based on site-
reported data that were independently monitored.
Determination of Medical Care Costs
Medical care costs for the index hospitalization and
for the 1-year follow-up period were assessed by a
combination of resource-based and event-based meth-
ods as described below. All costs were assessed from
the perspective of the U.S. health care system and are
reported in 2007 U.S. dollars.
Procedural Costs
Detailed resource use was recorded for each PCI
procedure, and the cost for each item was estimated on
the basis of the mean hospital acquisition cost for the
item at U.S. hospitals in 2007 (IMS Hospital Supply
Index, Millennium Research Group). The IMS Hospital
Supply Index reports national average acquisition costs
(weighted for volume purchased) for a broad range of
medical devices across a representative sample of US
hospitals. In particular, each DES was assigned a cost
of $2,200 and each bare metal stent was assigned a
cost of $800. Costs of antithrombotic therapy were
based on average wholesale prices from the Drug
Topics Red Book [16]. Costs of additional disposable
equipment, overhead and depreciation for the cardiac
catheterization laboratory, and non-physician personnel
were estimated using data from the micro-cost account-
ing systems of Saint Luke’s Mid America Heart Insti-
tute and Beth Israel Deaconess Medical Center and
adjusted for actual procedure duration. Costs for each
bypass operation including the pump circuit and associ-
ated disposable supplies were estimated in a similar
fashion. For analytic purposes, resource utilization and
cost data for the initial PCI procedure and any planned
staged PCI procedures were combined and reported as
the index procedural cost.
Other Hospital Costs
All other hospital costs associated with coronary re-
vascularization procedures were estimated using regres-
sion models based on SYNTAX-eligible Medicare
patients who underwent either PCI (n ¼ 116,883) or
CABG (n ¼ 41,710) and whose hospitalization data
were included in the 2007 Medicare Provider and
Review (MedPAR) database. For each hospitalization,
total costs were estimated by multiplying hospital
charges by the hospital and cost-center specific cost-to-
charge ratio [17,18]. We then constructed separate lin-
ear regression models for each procedure in which total
hospital costs were the dependent variable and inde-
pendent variables included sociodemographic factors,
comorbid conditions, and in-hospital complications
identified on the basis of ICD-9-CM codes [19,20]. Of
note, length of stay was not included as a predictor in
these models because of substantial differences in
length of stay across the countries that participated in
the SYNTAX trial. Finally, to avoid double-counting
procedural costs, the intercept for each model was
adjusted to remove the costs directly related to the
revascularization procedures themselves (based on
national averages for procedure duration and resource
use). Details of each model are provided in Supporting
Information Table I.
For hospitalizations that did not involve a revascu-
larization procedure, the hospital admission was
mapped to the appropriate diagnosis-related group
(DRG) based on the principal diagnosis and any proce-
dures performed during the admission. The cost for
each admission was then assigned based on mean Med-
icare reimbursement rates for the DRG obtained from
the Medicare Part A data file [21].
Physician Costs
Physician costs for revascularization procedures and
their associated hospitalizations were estimated based
on the Medicare fee schedule. For all other hospitaliza-
tions, physician costs were estimated as a percentage
of hospital costs according to DRG as previously
described [22,23].
Outpatient Cost
Costs for outpatient cardiovascular testing and proce-
dures as well as cardiac rehabilitation were estimated
using Medicare reimbursement rates. Outpatient medi-
cation use was assessed by patient self-report at the
time of each follow-up visit, and costs were assigned
using average wholesale prices from the Red Book
based on a weighted average of the three most fre-
quently used medications in each medication class
[16].
Quality of Life
Quality of life was assessed directly from patients at
baseline, 1, 6, and 12 months using the EuroQOL (EQ-
5D) health status instrument and converted to utility
weights using an algorithm developed for the U.S. pop-
ulation [24]. Quality-adjusted life expectancy was cal-
culated for each patient as the time-weighted average
of his or her utility values, using the mid-point
between assessments as the transition between health
states [25]. Missing utility values were estimated using
multiple imputation techniques, taking into account
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baseline patient characteristics, clinical events, number
of hospitalizations, and previous utility values.
Statistical Analysis
To avoid bias due to slightly higher rates of with-
drawal before treatment among patients assigned to
CABG, the analytic population for the primary eco-
nomic analysis consisted of all randomized patients for
whom complete data were available through 1-year of
follow-up (n ¼ 1740). Sensitivity analyses using the
full intention to treat population (n ¼ 1,800), the popu-
lation who underwent at least one revascularization
procedure (revascularized population, n ¼ 1,766) and
the population who were treated as assigned (per proto-
col population; n ¼ 1,739) demonstrated similar
results.
Categorical data are reported as frequencies, and
continuous data are reported as mean  standard devi-
ation. Discrete variables were compared by Fisher’s
exact test. Normally distributed continuous variables
were compared by Student’s t-test, and non-normally
distributed data were compared by the Wilcoxon rank-
sum test. Cost data are reported as both mean and me-
dian values and were compared by t-tests, which are
appropriate given the large sample size and our focus
on comparing mean costs between groups (rather than
the underlying distributions) [26]. Confidence intervals
for the differences in costs between the two treatment
groups were obtained using the bootstrap method [27].
Unless otherwise indicated, all analyses were per-
formed according to intention-to-treat.
Cost-Effectiveness Analyses
Cost-effectiveness was assessed from the perspective
of the U.S. healthcare system over the 1-year observa-
tion period. The primary endpoint for this analysis was
the incremental cost-effectiveness ratio (ICER) for the
more costly therapy (generally CABG) compared with
the less costly therapy, measured in terms of cost per
quality-adjusted year of life gained ($/QALY). Since the
main benefit of CABG during the timeframe of this
analysis was a reduction in the need for repeat revascu-
larization [15], a secondary cost-effectiveness analysis
was performed in terms of cost per repeat revasculariza-
tion event avoided. For each analysis, bootstrap methods
(1,000 replicates) were used to estimate the joint distri-
bution of cost and effectiveness differences and the pro-
portion of replicates with ICERs less than commonly
accepted benchmarks [28,29]. Stratified analyses of 1-
year costs, clinical outcomes, and cost-effectiveness were
TABLE I. Baseline Characteristics
All randomized patients (ITT) Economic analysis population
PCI (N ¼ 903) CABG (N ¼ 897) P value PCI (n ¼ 891) CABG (n ¼ 849) P value
Sociodemographic characteristics
Age, years 65.2  9.7 65.0  9.8 0.55 65.3  9.6 64.9  9.7 0.43
Male, % 76.4 78.9 0.20 76.3 79.9 0.08
Body mass index (kg/m2) 28.1  4.8 27.9  4.5 0.37 28.1  4.8 27.9  4.4 0.26
Enrolling country, %
United States 13.6 13.6 0.99 13.6 13.3 0.87
Rest of world 86.4 86.4 0.99 86.4 86.7 0.87
Clinical characteristics
Treated diabetes, % 28.2 28.5 0.89 28.2 27.9 0.91
Insulin-dependent, % 9.9 10.4 0.72 9.9 10.2 0.80
Current smoker, % 18.5 21.9 0.08 18.2 21.8 0.07
Previous myocardial infarction, % 31.9 33.8 0.32 31.8 33.5 0.45
Peripheral vascular disease, % 9.1 10.6 0.28 9.2 10.5 0.37
Chronic obstructive pulmonary disease, % 7.9 9.3 0.29 7.7 9.3 0.24
Prior stroke or transient ischemic attack, % 7.7 9.1 0.28 7.6 9.1 0.27
History of congestive heart failure, % 4.0 5.3 0.18 4.1 5.0 0.33
Left ventricular ejection fraction, % 59  13 58  13 0.32 59  13 58  13 0.31
Left main disease (any), % 39.5 38.8 0.75 39.8 39.6 0.91
Left main þ 0/1/2 vessel disease, % 24.5 25.2 0.72 24.7 25.7 0.60
Left main þ three-vessel disease, % 15.1 13.6 0.38 75.3 74.3 0.42
Three-vessel disease (no left main), % 60.5 61.2 0.75 60.2 60.4 0.91
Number of lesions 3.9  1.7 4.0  1.7 0.44 3.9  1.7 4.0  1.7 0.73
SYNTAX score 28.4  11.5 29.1  11.4 0.19 28.4  11.5 29.1  11.3 0.19
Initial treatment received, %
PCI 98.0 1.8 < 0.001 98.5 1.9 < 0.001
CABG 1.2 95.2 < 0.001 1.0 97.5 < 0.001
None 0.8 3.0 < 0.001 0.4 0.6 0.75
CABG ¼ coronary artery bypass grafting; ITT ¼ intent to treat; PCI ¼ percutaneous coronary intervention.
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performed according to prespecified subgroups defined by
gender, age terciles, diabetic status, the presence of signifi-
cant left main disease, enrolling country (U.S. vs. others),
and SYNTAX score terciles (a measure of angiographic
complexity) [15].
The authors had full access to the data and take
responsibility for its integrity. All authors have read
and agree to the manuscript as written.
RESULTS
Patient Population
A total of 1,800 patients with either three-vessel or
left main coronary disease were randomized to either
PCI with paclitaxel-eluting stents (n ¼ 903) or bypass
surgery (n ¼ 897). One-year follow-up was available
for 891 patients assigned to initial PCI and 849
patients assigned to initial CABG. Baseline characteris-
tics were well-matched within the overall study popula-
tion as well as among those patients for whom follow-
up data were available (Table I).
Initial Treatment Costs
Among patients assigned to PCI, 98% underwent ini-
tial PCI, 1.2% underwent CABG, and 0.8% underwent
no revascularization (Table I). Among patients assigned
to initial CABG, 95.2% underwent CABG, 1.8% under-
went PCI, and 3.0% underwent no procedure. Resource
utilization for the initial revascularization procedures
(including any staged PCI procedures) is summarized in
Table II. Among patients treated with initial PCI, 14.0%
required two planned procedures and 0.1% required
three planned procedures. On average, the index PCI
procedures required 2.1 guiding catheters (range 1–15),
3.5 guidewires (range 1–19), 3.7 angioplasty balloons
(range 0–21), and 4.5 DES (range 0–14). Although pro-
cedure duration was substantially shorter for PCI than
for CABG, total cost for the index procedure(s) was
$6,000/patient higher with PCI ($14,407 vs. $8,100, P
< 0.001) reflecting the much higher cost of consumable
resources for the PCI procedures.
Resource utilization and costs for the initial hospital-
ization (including repeat hospitalizations for staged
procedures) are summarized in Table III. There were
no differences in death or MI between the treatment
groups, but post-procedural stroke was more frequent
with CABG. Several other in-hospital complications
were more common among patients assigned to CABG
as well including respiratory failure, renal failure, seri-
ous infections, and atrial fibrillation. On the other
hand, the need for unplanned PCI was more common
among patients assigned to initial PCI. Not surpris-
ingly, post-procedure length of stay (9.4 vs. 3.3 days)
and ICU duration (2.4 vs. 0.9 days) were both substan-
tially longer among patients assigned to initial CABG.
Although procedural costs were higher for the PCI
group, other hospital costs including room/ancillary
costs and costs for physician services were substan-
tially higher with CABG. As a result, total costs for
the index revascularization procedures and associated
hospitalization were $5,693/patient higher for the
CABG group compared with the PCI group (95% CI:
$4,699 to $6,689; P < 0.001).
Follow-up Resource Utilization and Costs
During the 1-year follow-up period, cardiovascular
resource utilization was substantially greater among
patients assigned to initial PCI as compared with
CABG (Table IV). In particular, patients assigned to
initial PCI experienced higher rates of repeat revascu-
larization (14.1 vs. 4.8 procedures per 100 patients
treated) and cardiovascular hospitalizations (18.9 vs.
12.1 per 100 patients) during follow-up. As a result,
costs for re-hospitalization were $1,502/patient higher
after initial PCI with parallel increases in follow-up
physician costs and outpatient costs. Costs for cardio-
vascular medications were $1,247/patient higher after
initial PCI—driven almost entirely by the cost of
TABLE II. Index Procedural Resource Utilization and Cost
(Per Protocol Population)
PCI
(N ¼ 885)
CABG
(N ¼ 854) P value
Number of PCI procedures, %
1 85.9 –
2 14.0 –
3 0.1 –
Procedure duration (minutes)
Index procedure 91  44 209  62 <0.001
Staged procedures 10.2  29.7 –
Total 101  55 209  62 <0.001
Guiding catheters 2.1  1.2 –
Guidewires 3.5  2.3 –
Paclitaxel-eluting stents 4.5  2.3 –
Bare metal stents 0.0  0.3 –
Angioplasty balloons 3.7  2.8 –
Rotablator burrs 0.1  0.3 –
Intravascular ultrasound
catheters
0.1  0.4 –
Contrast volume, ml 415  203 –
Antithrombotic agents used, %
Bivalirudin 7.2 –
Abciximab 15.6 –
Eptifibatide 9.5 –
Tirofiban 10.7 –
Index procedure costs, $ 14,407  6,887
[13,537]
8,100  1,878
[7,959]
<0.001
CABG ¼ coronary artery bypass grafting; PCI ¼ percutaneous coronary
intervention.
Values in brackets are medians.
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prolonged dual antiplatelet therapy. On the other hand,
costs for rehabilitation services were substantially
lower after initial PCI compared with CABG
Overall, follow-up medical care costs averaged
$8,426 after PCI versus $6,143 after CABG—a differ-
ence of $2,282/patient (95% CI: $1,304–$3,261).
Despite these lower follow-up costs after CABG,
total 1-year costs remained $3590/patient higher with
initial CABG as compared with initial PCI (95% CI:
$2,124–$5,056). The net 1-year cost difference was
similar when the analysis was performed among all
patients who underwent revascularization ($3,411) or
among the per protocol population ($3,622).
Cost-Effectiveness
Although there was no significant difference in 1-year
survival between the two groups, quality-adjusted life
expectancy was greater for the PCI group as compared
with the CABG group (0.82 vs. 0.80 QALYs, P ¼
0.003)—driven largely by differences in utility weights
during the early recovery period (Baseline: PCI-0.75 vs.
CABG-0.74, P ¼ 0.11; 1-month: 0.85 vs. 0.77, P <
0.001; 6-months: 0.86 vs. 0.85, P ¼ 0.09; 12-months:
0.86 vs. 0.85, P ¼ 0.92 ). Thus, in our primary cost-
effectiveness analysis, PCI was an economically domi-
nant treatment strategy with both lower overall costs and
greater quality-adjusted life expectancy at 1-year. Boot-
strap simulation demonstrated that PCI remained eco-
nomically dominant in 100% of replicates (Fig. 1).
In our secondary cost-effectiveness analysis (in
which avoidance of the need for repeat revasculariza-
tion was the measure of clinical benefit), the ICER for
CABG versus PCI was $35,491 per repeat revasculari-
zation avoided. Bootstrap simulation demonstrated that
this ratio remained >$10,000 in 100% of replicates
and >$20,000 per repeat revascularization avoided in
94.1% (Fig. 2).
Subgroup Analyses
Results from stratified analyses according to prespeci-
fied baseline characteristics are displayed in Tables V
and VI. There were significant interactions between
treatment assignment and total 1-year cost according to
the presence of diabetes, left main disease, and SYN-
TAX score. The interaction with SYNTAX score was
particularly strong with a 1-year cost difference of
$6,154/patient among patients with SYNTAX scores <
23, $3,889/patient for those with SYNTAX scores 23–32
and only $466/patient for those with SYNTAX scores
>32. There was also a statistically significant interaction
between treatment assignment and SYNTAX score for
quality-adjusted life expectancy with differences ranging
TABLE III. Index Hospitalization Events, Resource Utilization, and Costs (Revascularized Population)
PCI (N ¼ 896) CABG (N ¼ 870) Difference (95% CI) P value
Death, % 1.8 1.4 0.4 (0.8 to 1.6) 0.27
Myocardial infarction, % 2.7 2.4 0.3 (12 to 1.7) 0.72
Stroke, % 0.1 1.0 0.9 (1.6 to 0.2) 0.01
Unplanned PCI, % 1.8 0.5 1.3 (0.3 to 2.3) 0.008
Unplanned CABG, % 0.8 1.1 0.04 (1.3 to 0.5) 0.22
Staged PCI, % 13.6 0.2 13.4 (11.1 to 15.7) <0.001
Complications, %
Major bleeding 4.5 4.8 0.4 (2.3 to 1.6) 0.72
Respiratory failure 0.0 1.6 1.6 (2.4 to 0.8) <0.001
Renal failure 0.7 2.4 1.7 (2.9 to 0.6) 0.003
Wound infection 0.0 4.1 4.1 (5.5 to 2.8) <0.001
Other infection 0.4 2.2 1.7 (2.8 to 0.7) 0.001
Atrial fibrillation 1.3 17.9 16.6 (19.2 to 13.9) <0.001
Cardiac tamponade 0.3 0.8 0.5 (1.2 to 0.2) 0.22
Other procedures, %
Permanent pacemaker 0.2 0.6 0.4 (0.9 to 0.2) 0.28
Implantable cardioverter-defibrillator
implantation
0.0 0.2 0.2 (0.5 to 0.1) 0.24
Carotid endarterectomy 0.0 0.5 0.5 (0.9 to 0.0) 0.06
Length of stay (post-procedure), days
Intensive care unit /cardiac care unit 0.9  1.9 [0] 2.4  3.9 [1] 1.5 (1.7 to 1.2) <0.001
Total 3.3  4.5 [2] 9.4  7.4 [7] 6.0 (6.6 to 5.5) <0.001
Initial hospitalization costs, $
Procedural costs 14,509  7,014 [13,527] 8,206  2,154 [7,973] 6,303 (5,815 to 6,791) <0.001
Hospital stay þ ancillary services 10,909  6,205 [8,094] 20,536þ8,634 [17,763] 9,626 (10,327 to 8,926) <0.001
Physician fees 2,141  939 [1,778] 4,511  807 [4,267] 2,370 (2,451 to 2,288) <0.001
Total 27,560  11,443 [24,729] 33,254  9,782 [30,554] 5,693 (6,689 to 4,699) <0.001
CABG ¼ coronary artery bypass grafting; CI ¼ confidence interval; PCI ¼ percutaneous coronary intervention.
Values in brackets are medians.
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from 0.056 QALYs in favor of PCI for the lowest SYN-
TAX score tercile versus 0.011 QALYs in favor of
CABG for the highest SYNTAX score tercile.
These interactions led to important differences in the
incremental cost-effectiveness of CABG versus PCI
according to SYNTAX score. Whereas PCI was an
economically dominant strategy for patients with low
and intermediate SYNTAX scores, for patients in the
highest SYNTAX score tercile, the ICER for CABG
versus PCI was $43,486/QALY gained and remained
$50,000/QALY in 48.9% of bootstrap simulations.
Similar findings were noted in the disease-specific
cost-effectiveness analysis. The ICER for CABG ver-
sus PCI ranged from $78,660/repeat revascularization
avoided in the lowest SYNTAX score tercile to
$3,602/repeat revascularization avoided in the highest
SYNTAX score tercile (with 68% of bootstrap repli-
cates < $10,000/repeat revascularization avoided).
TABLE IV. Follow-up Events, Resource Utilization, and Costs (Revascularized Population)
PCI (N ¼ 896) CABG (N ¼ 870) Difference (95% CI) P value
Clinical outcomes
Repeat revascularization, %
PCI 10.2 4.1 6.0 (3.6 to 8.4) <0.001
CABG 2.0 0.1 1.9 (0.9 to 2.8) <0.001
Any 11.6 4.1 7.5 (5.0 to 9.9) <0.001
Re-hospitalization, %
Cardiovascular 15.8 10.2 5.6 (2.5 to 8.7) <0.001
Non-cardiovascular 22.2 21.7 0.5 (3.4 to 4.3) 0.81
Any 32.4 27.6 4.8 (0.5 to 9.0) 0.03
Resource utilization (events/100 pts)
Repeat revascularization, n/100 pts
PCI procedures 11.9  38.7 4.7  23.8 7.2 (4.2 to 10.2) <0.001
CABG procedures 2.1  15.2 0.1  3.4 2.0 (1.0 to 3.0) <0.001
Total procedures 14.1  43.9 4.8  24.5 9.2 (5.9 to 12.6) <0.001
Diagnostic catheterization, n/100 pts 11.5  34.6 3.6  19.7 7.9 (5.3 to 10.6) <0.001
Re-hospitalization, n/100 pts
Cardiovascular 18.9  48.6 12.1  37.8 6.8 (2.7 to 10.9) 0.001
Non-cardiovascular 30.8  67.4 31.5  74.3 0.7 (7.3 to 5.9) 0.84
Total 49.7  86.7 43.6  88.1 6.1 (2.1 to 14.3) 0.14
Follow-up Costs
Re-hospitalizations, $
Cardiovascular 3,978  9,179 [0] 2,041  5,428 [0] 1,937 (1,231 to 2,644) <0.001
Non-cardiovascular 479  2,422 [0] 914  3,663 [0] 435 (724 to 146) 0.003
Total 4,457  9,460 [0] 2,955  6,616 [0] 1,502 (738 to 2,266) <0.001
Physician fees, $ 1,058  1,948 [0] 829  1,751 [0] 230 (57 to 403) 0.009
Outpatient services, $ 441  943 [0] 303  700 [0] 139 (61 to 216) <0.001
Rehabilitation services, $ 218  1,101 [0] 1,052  102 [0] 834 (979 to 690) <0.001
Medications, $ 2,253  857 [2,165] 1,006  768 [741] 1,247 (1,171 to 1,323) <0.001
Total follow-up cost, $ 8,426  11,750 [2,839] 6,143  8,983 [2,958] 2,282 (1,304 to 3,261) <0.001
Cumulative outcomes and costsa
Death, % 4.4 3.5 0.8 (1.0 to 2.7) 0.37
Myocardial infarction, % 4.8 3.3 1.5 (0.3 to 3.4) 0.11
Stroke, % 0.6 2.2 1.7 (2.8 to 0.6) 0.003
Repeat revascularization, % 13.5 5.9 7.6 (4.8 to 10.3) <0.001
Quality-adjusted life years 0.82  0.19 0.80  0.16 0.02 (0.01 to 0.04) 0.003
Total 1-year cost, $ 35,991  17,149 [30,720] 39,581  13,753 [34,496] 3,590 (5,056 to 2,124) <0.001
aTotal 1-year costs and QALYs are based on the population with complete economic data (n¼ 891 PCI, 849 CABG) and are analyzed by intention to treat.
CABG ¼ coronary artery bypass grafting; CI ¼ confidence interval; PCI ¼ percutaneous coronary intervention.
Fig. 1. Scatter plot showing the joint distribution of the differ-
ence in cost and quality-adjusted life expectancy between PCI
and CABG at 1-year according to bootstrap simulation (1,000
replicates). The lines indicate ICER thresholds of $50,000/QALY
gained (long dashes) and $100,000/QALY gained (short dashes).
[Color figure can be viewed in the online issue, which is avail-
able at wileyonlinelibrary.com.]
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DISCUSSION
This is the first direct economic comparison of PCI
using DES versus CABG for patients with three-vessel
and left main CAD. Within this highly complex patient
population, we found that although PCI required an av-
erage of 4.5 stents and incurred procedural costs of
>$14,000/patient, initial treatment costs were $6,000
per patient higher with CABG-reflecting a combination
of higher costs for the hospitalization and ancillary
services, more frequent complications, and higher phy-
sician fees. Over the first year, however, patients
assigned to CABG underwent fewer repeat revasculari-
zation procedures and lower medication costs, resulting
in cost offsets of $2,500/patient. Nonetheless, for the
overall population, total 1-year medical care costs
remained $3,500/patient higher with CABG than
with PCI. Since there were early differences in QOL
that favored PCI but no late differences in either QOL
or survival between the two groups, quality-adjusted
life expectancy also tended to favor PCI. Taken to-
gether, these results suggest that for the ‘‘average’’
SYNTAX patient, PCI was an economically dominant
strategy (with lower costs and greater quality-adjusted
life expectancy) over the first year of follow-up.
The results of prespecified subgroup analyses sug-
gest a somewhat more complex pattern, however. In
particular, we found that both clinical and economic
differences between CABG and PCI were highly de-
pendent on angiographic complexity. For patients with
low (<23) or intermediate (23–32) SYNTAX scores,
PCI remained economically dominant with 1-year cost
savings of $3,800–$6,100 and quality-adjusted life ex-
pectancy benefits of 0.013–0.048 QALYs. On the other
hand, for patients with high (>32) SYNTAX scores,
total 1-year costs were similar for PCI and CABG and
quality-adjusted life expectancy tended to favor
CABG, resulting in a favorable ICER for CABG of
$43,000/QALY gained. These results parallel those
for the primary clinical outcome of the SYNTAX trial,
which did not differ significantly between PCI and
CABG for patients with low or intermediate SYNTAX
scores but strongly favored CABG for patients with
high SYNTAX scores [15].
Fig. 2. Scatter plot showing the joint distribution of the differ-
ence in cost and repeat revascularization events between PCI
and CABG at 1-year according to bootstrap simulation (1,000
replicates). The lines indicate ICER thresholds of $10,000 per
repeat revascularization avoided (long dashes) and $20,000 per
repeat revascularization avoided (short dashes). [Color figure
can be viewed in the online issue, which is available at wileyon-
linelibrary.com.]
TABLE V. Subgroup Analyses—Cost Per Quality-Adjusted Life Year Gained (CABG vs. PCI)
Subgroup D Cost (95% CI) Pint DQALYs (95% CI) Pint
ICER for CABG
($/QALY)
% < $50K per
QALY gained
Overall (n ¼ 1,740) 3,590 (5,056 to 2,124) – 0.016 (0.001 to 0.033) – PCI Dominant 0.0
Male (n ¼ 1,358) 4,192 (5,771 to 2,614) 0.12 0.017 (0.000 to 0.034) 0.62 PCI Dominant 0.0
Female (n ¼ 382) 1,728 (5,364 to 1,908) 0.027 (0.016 to 0.071) PCI Dominant 9.9
Age < 61 (n ¼ 600) 4,157 (6,401 to 1,914) 0.75 0.027 (0.003 to 0.052) 0.63 PCI Dominant 0.0
Age 62–70 (n ¼ 589) 3,275 (5,687 to 864) 0.003 (0.023 to 0.029) PCI Dominant 1.1
Age > 70 (n ¼ 551) 3,480 (6,432 to 527) 0.019 (0.018 to 0.056) PCI Dominant 1.0
Diabetes (n ¼ 488) 1,289 (4,409 to 1,829) 0.02 0.019 (0.019 to 0.058) 0.85 PCI Dominant 13.6
No diabetes (n ¼ 1,252) 4,500 (6,120 to 2,879) 0.015 (0.003 to 0.033) PCI Dominant 0.0
LM disease, any (n ¼ 691) 6,341 (8,729 to 3,954) <0.001 0.032 (0.005 to 0.058) 0.15 PCI Dominant 0.0
Three-vessel disease, no LM
(n ¼ 1,301)
1,768 (3,609 to 74) 0.006 (0.016 to 0.028) PCI Dominant 5.3
SYNTAX score <23 (n ¼ 554) 6,154 (8,599 to 3,709) 0.001 0.048 (0.018 to 0.077) 0.007 PCI Dominant 0.0
SYNTAX score 23–32 (n ¼ 590) 3,889 (6,345 to 1,433) 0.013 (0.014 to 0.041) PCI Dominant 0.3
SYNTAX score >32 (n ¼ 589) 466 (3,132 to 2,199) 0.011 (0.042 to 0.020) 43,486 48.9
U.S. patients (n ¼ 234) 7,897 (12,423 to 3,371) 0.02 0.011 (0.033 to 0.053) 0.85 PCI Dominant 0.0
Non-U.S. patients (n ¼ 1,506) 2,930 (4,467 to 1,391) 0.017 (0.001 to 0.034) PCI Dominant 0.0
CABG ¼ coronary artery bypass grafting; CI ¼ confidence interval; ICER ¼ incremental cost-effectiveness ratio; LM ¼ left main; PCI ¼ percutane-
ous coronary intervention; QALY ¼ quality-adjusted life year.
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Comparison with Previous Studies
Over the past 20 years, numerous studies have eval-
uated the cost-effectiveness of PCI versus CABG
among patients with multivessel coronary disease. In
general, these studies have demonstrated much higher
initial revascularization costs with CABG and lower
costs during follow-up, resulting in roughly comparable
costs over the long-term [7,8,30–36]. Only three stud-
ies, however, have been performed from the perspec-
tive of the U.S. healthcare system.
The bypass angioplasty revascularization investiga-
tion (BARI) compared conventional balloon angio-
plasty and CABG among 1,829 patients with two- or
three-vessel disease. Although initial costs were
$11,000 higher with CABG, by 1-year this difference
had narrowed to $5,000 and by 5-years the difference
was $2,500 with an ICER of $26,117 per year of life
gained [7]. Among the 387 BARI patients with three-
vessel CAD, CABG was an economically dominant
strategy with lower costs and better survival. Extended
follow-up to 12-years demonstrated roughly compara-
ble results [30].
The Emory angioplasty versus surgery trial (EAST)
randomized 392 patients with two- or three-vessel
CAD (60% two-vessel disease) to balloon angioplasty
or CABG. Initial hospital costs were $8,000/patient
higher with CABG, but this difference decreased to
$1,500/patient by 3-years [8] with similar results at
8-years [31]. A formal cost-effectiveness analysis was
not performed.
Most recently, Stroupe et al. reported the results of
an economic evaluation performed alongside the An-
gina with Extremely Serious Operative Mortality Eval-
uation (AWESOME) trial [37]. They randomized 454
patients with an urgent need for revascularization and
who had one or more high risk features for CABG to
either CABG or PCI (using a combination of balloon
angioplasty and bare metal stents). In contrast to most
other studies, the AWESOME trial demonstrated little
difference in follow-up costs; the initial cost difference
of $24,000/patient (higher with CABG) only
decreased to $20,000 by 3-years and remained nearly
$19,000 at 5-years. Coupled with improved survival in
the PCI group, the AWESOME investigators concluded
that for patients requiring urgent revascularization and
at high risk of complications, PCI was an economically
dominant strategy.
The SYNTAX economic study thus extends previous
research in several ways. Most importantly, our study
is the first prospective economic evaluation of PCI
with DES versus CABG. Since the main limitation of
previous PCI strategies has been restenosis leading to
frequent repeat revascularization, it might be expected
that the lower restenosis rates seen with DES would
translate into more durable economic benefit. Indeed,
we found that follow-up hospital costs were only
$1,500 higher with PCI than with CABG—a much
lower difference than had been reported previously.
Moreover, our study extends the population of patients
for whom comparative economic data are available to
patients with the most complex forms of CAD includ-
ing left main disease. Based on the SYNTAX data, it
appears that patients with left main disease may derive
substantial economic advantage from a DES–PCI strat-
egy. Since the overall clinical trial failed to meet its
primary endpoint, however, these findings should be
TABLE VI. Subgroup Analyses—Cost Per Repeat Revascularization Avoided (CABG vs. PCI)
Subgroup D Cost (95% CI) Pint
D Repeat Revasc
(events/100
patients) (95% CI) Pint
ICER for CABG
($/RR avoided)
% < $10K per
RR avoided
Overall (n ¼ 1,740) 3,590 (5,056 to 2,124) – 10.1 (6.5 to 13.9) – 35,491 0.0
Male (n ¼ 1,358) 4,192 (5,771 to 2,614) 0.12 9.2 (5.1 to 13.5) 0.29 45,356 0.0
Female (n ¼ 382) 1,728 (5,364 to 1,908) 13.2 (5.6 to 21.1) 13,072 41.6
Age < 61 (n ¼ 600) 4,157 (6,401 to 1,914) 0.75 6.9 (1.6 to 12.7) 0.20 60,111 0.3
Age 62–70 (n ¼ 589) 3,275 (5,687 to 864) 11.2 (4.8 to 17.3) 29,225 6.3
Age > 70 (n ¼ 551) 3,480 (6,432 to 527) 12.4 (5.7 to 20.4) 28,095 8.9
Diabetes (n ¼ 488) 1,289 (4,409 to 1,829) 0.02 13.6 (8.4 to 24.4) 0.20 7,895 56.7
No diabetes (n ¼ 1,252) 4,500 (6,120 to 2,879) 7.7 (3.4 to 11.9) 58,630 0.0
LM disease, any (n ¼ 691) 6,341 (8,729 to 3,954) <0.001 7.2 (1.4 to 13.5) 0.14 88,377 0.0
Three-vessel disease, no LM
(n ¼ 1,301)
1,768 (3,609 to 74) 12.1 (7.5 to 17.1) 14,664 30.1
SYNTAX score <23 (n ¼ 554) 6,154 (8,599 to 3,709) 0.001 7.8 (1.0 to 15.6) 0.23 78,660 0.1
SYNTAX score 23–32 (n ¼ 590) 3,889 (6,345 to 1,433) 9.4 (3.7 to 15.7) 41,604 2.7
SYNTAX score >32 (n ¼ 589) 466 (3,132 to 2,199) 13.0 (6.8 to 19.2) 3,602 68.0
U.S. patients (n ¼ 234) 7,897 (12,423 to 3,371) 0.02 4.4 (15.8 to 6.4) <0.001 PCI Dominant 0.1
Non-U.S. patients (n ¼ 1,506) 2,930 (4,467 to 1,391) 12.4 (8.6 to 16.3) 23,696 3.6
CABG ¼ coronary artery bypass grafting; CI ¼ confidence interval; ICER ¼ incremental cost-effectiveness ratio; LM ¼ left main; PCI ¼ percutane-
ous coronary intervention; QALY ¼ quality-adjusted life year; RR ¼ repeat revascularization.
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considered hypothesis-generating and will require inde-
pendent confirmation.
Study Limitations
Our study has several important limitations. First, as
with any clinical trial, our results may not be applica-
ble to all patients with three-vessel or left main CAD-
many of whom were excluded from randomization on
the basis of unfavorable anatomy for PCI or excessive
surgical risk. These patients were treated in parallel
nested registries that were not included in this study.
Second, although our analysis was performed from the
perspective of the U.S. healthcare system, it was based
on data collected from patients who were enrolled and
treated in 18 countries of which only 15% were
actually treated in the U.S. (Supporting Information Ta-
ble II). Although it would have been possible to restrict
the economic analysis to U.S. patients, given the limited
sample size we felt that this approach would have led to
highly unstable results. Instead, we used costing method-
ology that depended only on the assumption that clinical
outcomes and complications (the primary determinants
of cost) would be similar across healthcare systems
[38]—an assumption that underlies the design of the
overall trial as well. It is also important to recognize that
extension of our economic analysis to other health care
systems may demonstrate very different results because
of different cost and payment structures.
Moreover, although we used the most current cost
data available at the time of the analysis, changes in
unit costs since 2007 (particularly for DES) may have
altered the relative cost of the two strategies somewhat.
Recently, several clinical trials have demonstrated that
the paclitaxel drug-eluting stent that was used in the
SYNTAX trial has higher rates of target lesion revas-
cularization and MI compared with the second-genera-
tion everolimus-eluting stent [39,40]. Whether use of
everolimus-eluting stents would have increased the
economic advantage of PCI is unknown.
Finally, the time frame encompassed by our study is
relatively brief compared with the life expectancy of
the underlying population. Nonetheless, previous stud-
ies have demonstrated that cost differences between
PCI and CABG are minimal beyond the first 2–3 years
[30,31] suggesting that even a shorter follow-up dura-
tion may provide useful insight. On the other hand, if
meaningful differences in long-term survival emerge
either within the overall SYNTAX population or im-
portant subgroups, it will be important to incorporate
these benefits in future economic assessments. Indeed,
5-year clinical and economic follow-up is currently
planned for the SYNTAX trial and will be the subject
of separate reports at that time.
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